Rituximab in primary conjunctiva lymphoma

Leuk Res. 2005 Jan;29(1):107-8. doi: 10.1016/j.leukres.2004.05.011.

Abstract

Our experience with a patient with a primary conjunctiva lymphoma who was treated with conventional dose of rituximab obtaining a complete response without acute and late local toxicity for the eye.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / metabolism
  • Antineoplastic Agents / therapeutic use*
  • Conjunctival Neoplasms / drug therapy*
  • Conjunctival Neoplasms / immunology
  • Female
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab